2022 American Transplant Congress
Tissue Engineering Scaffolds for Minimally Invasive Immunosurveillance of Acute Cellular Graft Rejection
*Purpose: As there is no assay to predict the risk of acute cellular allograft rejection (ACAR), clinicians rely on protocol graft biopsy and aggressive, one-size-fits-all…2022 American Transplant Congress
Two-Week Protocol Biopsy in Renal Allograft: Feasibility, Safety, and Outcomes
*Purpose: Protocol biopsy in renal allograft helps to early detect subclinical rejection (SCR) in patients who have no abnormal clinical and laboratory findings. Still, there…2022 American Transplant Congress
Very Low Frequency of Pathological Findings in One-Year Protocol Biopsies of Low-Risk Kidney Transplant Recipients – Results from the Nordic Protocol Biopsy Study
*Purpose: The clinical usefulness of kidney graft protocol biopsies have been debated. We studied the frequency of borderline and T-cell-mediated rejection (TCMR) in one-year protocol…2022 American Transplant Congress
Surveillance with Protocol Biopsies for Rejection Significantly Impacts Survival Following Intestine Transplant
*Purpose: Frequent surveillance biopsy is required on the first month post intestinal transplant(IT) due to high-risk of acute rejection. However, the utility and the frequency…2022 American Transplant Congress
Plasmapheresis and Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence Post-Kidney Transplantation
*Purpose: Primary focal segmental glomerulosclerosis (FSGS) recurs after kidney transplantation (KT) in 30-50% of recipients with a median time of 1.5 months post-KT. Recurrence is…2022 American Transplant Congress
Performance of Donor Derived Cell Free DNA (dd-cfDNA) in Diagnosing Subclinical and Clinical Acute Rejection in Kidney Transplant Recipients
*Purpose: The aim of this study was to examine the performance of Viracor TRAC donor derived cell free DNA (dd-cfDNA) in for-cause biopsies as well…2022 American Transplant Congress
Trends in Donor Derived Cell Free DNA Before and After Cellular and Antibody Mediated Rejection
1Northwestern University, Chicago, IL, 2Transplant nephrology, Northwestern University, Chicago, IL
*Purpose: The TRAC dd-cfDNA test was developed to detect acute kidney transplant rejection but can also detect subclinical rejection with improved performance in antibody-mediated rejection…2021 American Transplant Congress
A Reliable Non Invasive Alternative to Surveillance Renal Allograft Biopsy
Transplant Nephrology, University of Alabama Birmingham, Birmingham, AL
*Purpose:Surveillance Renal Allograft Biopsy (SAVB) is the standard of care to identify subclinical immunological injury(SCI). However fewer than 25% of transplant centers in the US…2020 American Transplant Congress
The UCSF Cardiovascular Risk after Kidney Transplantation (CARAKTER) Study
1UCSF, San Francisco, CA, 2UC Davis, Sacramento, CA
*Purpose: We established the UCSF CARAKTER (Cardiovascular Risk After Kidney Transplantation) Study in order to evaluate risk factors for cardiac disease onset and progression in…2020 American Transplant Congress
Impact of Timing of T Cell Mediated Rejection in the First Year after Kidney Transplantation
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: To evaluate the impact of timing of T-cell mediated rejection (TCMR) occurrence in the first year after kidney transplantation (KT).*Methods: Single center retrospective cohort…
- 1
- 2
- 3
- …
- 7
- Next Page »